Clinical trial NCT07015996: Efficacy of Tezepelumab in Peanut Oral Immunotherapy
Official title: Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Peanut Allergy
Keywords: Tezepelumab
Peanut
Oral Immunotherapy
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor class: NIH
Collaborators: name: Immune Tolerance Network (ITN)
name: PPD Development, LP
name: Rho Federal Systems Division, Inc.
First posted: 2025-06-11
Enrollment: 62
Sex: ALL
Minimum age (years): 12
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for the treatment of peanut allergy. Study participation is divided into 3 periods: (i) a monotherapy period comprised of injections of either Tezepelumab or placebo from week 0 to week 8, (ii) followed by a combination therapy period comprised of 56 weeks during which peanut OIT is built up and maintained, and (iii) a treatment withdrawal period comprised of 12 weeks. This study will enroll 62 peanut-allergic individuals from 12 to 55 years of age who experience dose-limiting symptoms to \<=100 mg of peanut protein in a single dose (\<= 144 mg cumulative dose) as assessed by DBPCFC.

The primary objective is to determine whether 56 weeks of tezepelumab plus peanut OIT as compared to 56 weeks of placebo plus peanut OIT induces sustained unresponsiveness to peanut 12 weeks after stopping combination therapy.


Eligibility criteria: Inclusion Criteria:

1. Participant and/or parent/legal guardian must be able to understand and provide informed consent (parental permission and informed assent of minor, if applicable)
2. A personal history of an allergic reaction to peanut ingestion
3. A positive reaction at or below ingestion of 100 mg of peanut protein in a single dose (\<= 144 milligram cumulative dose) during the screening Double-Blind Placebo-Controlled Food Challenge (DBPCFC)
4. A negative challenge to the placebo (oat) during the Screening DBPCFC
5. Sensitization to peanut as evidenced by either one of the following:

   1. positive sIgE to Ara h2 \>= 0.35 kilounit per liter by ImmunoCAP (TM) testing, or
   2. wheal \>= 3 mm on skin prick test to peanut extract compared to a negative control
6. Female participants of childbearing potential must have a negative pregnancy test upon study entry
7. Female participants with reproductive potential must agree to use an FDA approved method of contraception for the duration of the study
8. Willing and able to comply with the study protocol requirements
9. Participants with other food allergies must agree to continue avoidance of these food items from their diet to avoid confounding the safety and efficacy data of the study

Exclusion Criteria:

1. Currently in build-up phase of aeroallergen immunotherapy
2. Current food allergen immunotherapy or use of any food allergen immunotherapy within the past 12 months
3. Pregnant, planning a pregnancy during the study, or breast-feeding
4. History of intolerance, hypersensitivity, or allergic reactions to tezepelumab, or the inactive ingredients (excipients) of tezepelumab, other IgG biologics, or rescue medications and their excipients
5. Allergy to oat (participant reported)
6. History of severe systemic allergic reaction to peanut with symptoms including the need for mechanical ventilation and/or severe hypotension requiring intensive care unit admission
7. Asthma requiring high dose inhaled corticosteroid therapy for control (2007 NHLBI Criteria Steps 5 or 6 in adults and adolescents)
8. History of a life-threatening asthma attack within 1 year before screening (e.g., requiring an ICU admission or intubation with mechanical ventilation), need for oral corticosteroids for asthma management within the last 6 months, or current Asthma Control Test score less than 19 at screening
9. History of ischemic cardiovascular disease or other cardiac disease, where, in the opinion of the site investigator, participation in the trial would pose a risk from participation in the study
10. History of eosinophilic gastrointestinal disease at screening
11. History of disease affecting the immune system such as autoimmune disease (e.g., systemic lupus erythematosus), immune complex disease (e.g., serum sickness), or immunodeficiency, where, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
12. History of malignancy of any type, excluding basal cell and squamous cell cancers of the skin that only required surgical excision or in situ carcinoma of the cervix study provided that curative therapy was completed at least 12 months prior to informed consent
13. Current known helminth infection
14. Positive QuantiFERON - TB Gold test or TB Gold Plus, or T-SPOT(R) TB test unless the potential participant has been treated with appropriate chemoprophylaxis. In the case of an indeterminate or borderline Interferon Gamma Release Assay (IGRA), an IGRA may be repeated
15. Any of the following:

    1. HIV
    2. current or prior infection with hepatitis B virus (HBV)
    3. current or prior infection with hepatitis C virus (HCV), except adequately treated HCV with sustained virologic response \>= 12 weeks
16. Active liver disease, defined as either:

    1. AST, ALT, and/or Alk phos \>2x ULN, or
    2. other active liver disease which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
17. Any of the following:

    1. Current use of beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers
    2. Received any investigational product within the past 4 months or 5 half-lives (whichever is longer) prior to screening
    3. Received systemic corticosteroids within 14 days prior to screening
    4. Receipt of immunoglobulin or other blood product within 30 days of screening
    5. Receipt of live attenuated vaccine within 30 days of informed consent
    6. Use of an immunosuppressant or immunomodulating drug within 30 days prior to screening
    7. Use of biologics targeting the human immune system within the past 12 months prior to screening
    8. Use of any herbal medications, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
18. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study

Primary outcomes:
measure: Consumption of a cumulative dose of 4000 mg of peanut protein without dose-limiting symptoms during the open Oral Food Challenge (OFC)
timeFrame: At week 76
Secondary outcomes:
measure: Highest single dose of peanut protein consumed without doselimiting symptoms during the open Oral Food Challenge (OFC)
timeFrame: At week 64 and 76
measure: Consumption of a cumulative dose of 4000 mg of peanut protein without doselimiting symptoms during the open Oral Food Challenge (OFC)
timeFrame: At week 64
measure: Highest cumulative dose of peanut protein consumed without dose limiting symptoms during the open Oral Food Challenge (OFC)
timeFrame: At week 64 and 76
measure: An adverse event related to monotherapy
timeFrame: During 8 weeks of therapy
measure: An adverse event related to combination therapy
timeFrame: During 56 weeks of therapy
measure: An adverse event related to tezepelumab plus peanut Oral Immunotherapy (OIT) discontinuation
timeFrame: 12 weeks after discontinuation of treatment
measure: An adverse event related to placebo plus peanut Oral Immunotherapy (OIT) discontinuation
timeFrame: 12 weeks after discontinuation of treatment
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology
state: Arkansas
city: Los Angeles
country: United States
facility: University of California, Los Angeles: Department of Medicine, Division of Clinical Immunology and Allergy
state: California
city: Baltimore
country: United States
facility: Johns Hopkins Children's Center: Department of Allergy & Immunology
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital: Department of Medicine: Allergy & Clinical Immunology Unit
state: Massachusetts
city: Boston
country: United States
facility: Boston Children's Hospital: Allergy and Asthma Program
state: Massachusetts
city: Ann Arbor
country: United States
facility: The University of Michigan: Division of Allergy and Clinical Immunology
state: Michigan
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology
state: New York
city: Chapel Hill
country: United States
facility: North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
state: North Carolina
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center: Division of Allergy and Immunology
state: Ohio
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center: Division of Allergy and Immunology
state: Texas
Study officials:
affiliation: North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
name: Edwin H Kim, M.D., M.S.
role: STUDY_CHAIR
affiliation: Massachusetts General Hospital: Department of Medicine: Allergy & Clinical Immunology Unit
name: Sarita Patil, M.D.
role: STUDY_CHAIR
References: